Eli Lilly & Co. will spend $5.3 billion to boost production of a key ingredient in its weight-loss and diabetes shots after the treatments’ explosive popularity led to shortages. The ...
Eli Lilly will invest an additional $5.3 billion into a new manufacturing site, boosting production for its weight loss and diabetes medications Mounjaro and Zepbound, the pharmaceutical firm said ...
Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro.
Shares of Eli Lilly (NYSE:LLY) reached new all-time highs this week, driven by the continued share price and fundamental momentum, and by what some would say is the obesity market hype. The former ...
Eli Lilly and Co., is more than doubling its investment in its Boone County manufacturing site to increase production of ingredients in its blockbuster weight loss and diabetes drugs. The ...
Walmart raised its full-year forecast and reported better-than-expected quarterly results on Thursday, betting that easing ...
China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will intensify the drugmaker’s rivalry with Novo Nordisk A/S over weight ...
, opens new tab to develop cancer therapies, making it eligible for milestone payments of up to $1.1 billion and royalties on sales. The Boston-based drug developer will use its proprietary ...